Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design

Background Carcinoma of unknown primary origin (CUP) accounts for 2%–5% of newly diagnosed advanced malignancies, with chemotherapy as the standard of care. CUPISCO (NCT03498521) is an ongoing randomized trial using comprehensive genomic profiling (CGP) to assign patients with CUP to targeted or imm...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2021-03, Vol.26 (3), p.e394-e402
Hauptverfasser:	Ross, Jeffrey S., Sokol, Ethan S., Moch, Holger, Mileshkin, Linda, Baciarello, Giulia, Losa, Ferran, Beringer, Andreas, Thomas, Marlene, Elvin, Julia A., Ngo, Nhu, Jin, Dexter X., Krämer, Alwin
Format:	Artikel
Sprache:	eng
Schlagworte:	Antimitotic agents Antineoplastic agents Biomarkers, Tumor - genetics Cancer Cancer Diagnostics and Molecular Pathology Carcinoma Chemotherapy Development and progression Gene Expression Profiling Genetic aspects Genetic profiling Genomics Humans Immunotherapy Loss of heterozygosity Lung Neoplasms Molecular targeted therapy Mutation Neoplasms, Unknown Primary - genetics Pharmaceutical industry Protein-Tyrosine Kinases Proto-Oncogene Proteins Retrospective Studies Unknown primary tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!